TAVI vs Surgical Aortic Valve Replacement: How Are They Different?

When severe aortic stenosis requires valve replacement, two established treatment options may be considered: transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR).

Both treatments replace a diseased aortic valve with a prosthetic valve, but they reach the heart in very different ways. TAVI delivers the replacement valve through a catheter, most commonly through an artery in the groin, while SAVR involves open-heart surgery to remove the diseased valve and sew a new valve into position.

Neither procedure is automatically the better choice for every patient. The decision depends on factors such as age, valve anatomy, overall health, surgical risk, life expectancy, vascular access and whether other heart problems need to be treated at the same time.

If you are looking for a broader explanation of the procedure, our guide to TAVI/TAVR treatment explains how transcatheter valve replacement works and where it fits into the treatment of aortic stenosis.

TAVI and SAVR: What is the basic difference?

The simplest way to understand the two procedures is to look at how the replacement valve reaches the heart. During TAVI, a folded replacement valve is mounted on a catheter and guided through a blood vessel to the heart. The new valve is positioned within the diseased aortic valve and expanded into place. The native valve is generally not surgically removed.

During SAVR, the patient undergoes surgery under general anaesthesia. The surgeon accesses the heart, removes the diseased aortic valve and sutures the replacement valve into position. This difference affects recovery, hospital stay, procedural risks and the types of patients for whom each approach may be most appropriate.

TAVI vs SAVR at a glance

Why might TAVI be preferred?

One of the major advantages of TAVI is that it avoids the large chest incision and cardiopulmonary bypass associated with conventional surgical valve replacement.

For many patients, particularly older adults, this can translate into an easier early recovery. Patients may experience less physical disruption from the procedure and can often return to normal activities sooner than after open-heart surgery.

Current evidence also shows that TAVI can provide excellent outcomes in appropriately selected patients with severe aortic stenosis. In the PARTNER 3 trial, seven-year outcomes in low-surgical-risk patients showed sustained improvement in health status after both TAVI and SAVR, while TAVI was associated with earlier recovery. However, a faster recovery does not mean that TAVI is automatically the better lifetime strategy for every patient.

Why might SAVR still be the better option?

Surgical valve replacement remains an important treatment because it provides the surgeon with direct access to the heart and allows other cardiac problems to be addressed during the same operation.

SAVR may be particularly attractive in younger patients who have a long expected lifespan, especially when future valve procedures need to be considered as part of a lifetime treatment plan.

Surgery can also be preferred when the patient has a bicuspid aortic valve, an aortic condition requiring surgical treatment, significant coronary artery disease requiring bypass surgery or another valve problem that needs to be corrected at the same time.

How does recovery differ?

Recovery is one of the clearest practical differences between the two procedures. After transfemoral TAVI, there is usually no large incision in the chest. Some patients can leave the hospital within a few days, although the actual length of stay depends on age, overall health, complications and the hospital's care pathway.

SAVR requires recovery from major chest surgery in addition to recovery from the valve replacement itself. Hospitalisation is generally longer, followed by a more gradual return to normal physical activity.

However, recovery varies considerably between individuals. A younger, otherwise healthy patient may recover from surgery differently from an older patient with several medical conditions.

Are the risks different?

Both procedures are major treatments for aortic stenosis and can have serious complications. The types and frequency of complications are not identical. TAVI can be associated with:

• Bleeding or complications involving the access blood vessels
• Stroke
• Conduction problems requiring a permanent pacemaker
• Paravalvular aortic regurgitation
• Kidney injury
• Valve malposition or other valve-related complications

SAVR can be associated with:

• Major bleeding
• Infection
• Stroke
• Kidney injury
• Complications related to open-heart surgery
• Atrial fibrillation and other rhythm problems
• A longer recovery period

What about pacemakers and valve leakage?

Two complications often discussed when comparing TAVI and SAVR are permanent pacemaker implantation and paravalvular leakage.

TAVI can affect the heart's electrical conduction system because the replacement valve is positioned close to the structures responsible for electrical signalling. Some patients therefore require a permanent pacemaker after the procedure.

Paravalvular leakage can occur when blood flows around the outside of a transcatheter valve rather than entirely through it. Contemporary TAVI devices have improved substantially, but the risk remains an important part of procedural planning.

In longer-term comparisons, differences in these complications remain relevant when deciding which treatment is most appropriate for a particular patient.

What about long-term valve durability?

This is one of the most important considerations when treating younger patients. Both TAVI and SAVR use bioprosthetic valves in many patients, and contemporary transcatheter valves have demonstrated encouraging mid-term durability. However, there is still less very-long-term evidence for TAVI than for surgical valves, particularly in younger patients who may live for several decades after their initial valve replacement.

The 2025 European guidelines specifically identify the need for more evidence about the long-term durability of transcatheter valves compared with surgical bioprosthetic valves in younger patients.

This does not mean that TAVI valves are considered short-lived. Rather, doctors need to think beyond the first procedure and consider what treatment options may be available if the valve eventually deteriorates.

Age can influence the choice

Age is now an important part of TAVI versus SAVR decision-making, but it should not be treated as an isolated rule. Under the 2025 ESC/EACTS recommendations, TAVI is recommended for patients aged 70 years or older with tricuspid aortic stenosis when the anatomy is suitable. For patients younger than 70 with low surgical risk, SAVR is recommended. Patients who do not clearly fall into these groups are assessed individually by the Heart Team.

The reason is straightforward: younger patients may have a longer lifetime during which they could require another valve intervention. Their anatomy, future treatment options and the possibility of combining valve replacement with other cardiac surgery therefore become especially important.

When TAVI and SAVR may both be reasonable

There are many patients for whom both approaches can be appropriate. In these situations, the decision may come down to a combination of clinical and personal factors. Doctors may consider:

• Age and expected lifespan
• Severity of symptoms and effect on daily life
• Aortic valve anatomy
• Presence of a bicuspid or tricuspid valve
• Condition of the arteries used for catheter access
• Overall surgical risk
• Frailty and other medical conditions
• Need for coronary bypass or other heart surgery
• Potential future valve interventions
• Patient preferences

Why the Heart Team matters

The choice between TAVI and SAVR is best made through a multidisciplinary Heart Team assessment. The team reviews the patient's clinical history, echocardiogram, CT findings, vascular anatomy and overall health. Cardiologists, interventional specialists, cardiac surgeons and other members of the care team may contribute to the decision.

Patient preference is also important when both options are medically reasonable. A treatment decision should take into account not only procedural risk, but also recovery expectations, long-term valve management and the patient's priorities.

So, which is better: TAVI or SAVR?

There is no universal winner. TAVI may have an advantage when a less invasive approach and faster early recovery are particularly valuable. This is especially relevant for many older patients with suitable anatomy.

SAVR may have an advantage when long-term lifetime valve planning, bicuspid anatomy or additional cardiac surgery makes an operation more appropriate.

Modern evidence shows that both procedures can provide durable clinical benefit in appropriately selected patients. The most suitable option depends on the individual rather than on a simple ranking of one procedure above the other.

The Bottom Line

TAVI and surgical aortic valve replacement are both established treatments for severe aortic stenosis, but they solve the same problem in different ways.

TAVI is less invasive and generally allows faster early recovery, making it an important option for many older patients with suitable anatomy. SAVR remains essential for many younger patients and for people whose valve anatomy or other cardiac conditions make surgery more suitable.

The choice should therefore not be based only on age, surgical risk or recovery time. A good decision considers the patient's current health, valve anatomy, life expectancy, associated heart conditions and future treatment options.

For many patients, the most appropriate question is not “Which procedure is better?” but rather “Which procedure is better for me, now and over the course of my lifetime?”